A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DA / dopamine agonist

[Related PubMed/MEDLINE]
Total Number of Papers: 236
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DA  (>> Co-occurring Abbreviation)
Long Form:   dopamine agonist
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells. NFPAs, PitNETs, SSAs
2020 Prolactinomas in pregnancy: considerations before conception and during pregnancy. MAC
2020 Surgery for prolactinomas: a better choice? DAs, TSS
2019 An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists. ---
2019 Clinical management of difficult to treat macroprolactinomas. MEN1
2019 DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma. CAB, mTOR, mTORC1, PA
2019 Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. ICD
2019 Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. ---
2019 Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. ---
10  2019 Epidemiology of impulse control disorders and association with dopamine agonist exposure, active component, U.S. Armed Forces, 2014-2018. AOR, CI, ICDs, p-yrs
11  2019 Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. HBI, ICDs, QUIP-S
12  2019 Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis. CI, OR, PAEs, RLS
13  2019 Parkinson's disease management and impulse control disorders: current state and future perspectives. DAWS, DRT, ICDs, PD
14  2019 Phenotype and resistance patterns of 10 resistant prolactinomas. CAB, PRL, RP
15  2019 Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure. PRL
16  2019 Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease. LED, LED-DA, MAOB-I, PD
17  2019 Role of gamma knife radiosurgery in the treatment of prolactinomas. GKRS
18  2019 Rotigotine Transdermal Patch: A Review in Parkinson's Disease. HRQoL, PD, TP
20  2018 A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease. ADRs, EOP, PD, UPDRS
21  2018 Camptocormia Induced by a Dopaminergic Agonist. PD
22  2018 Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. CD, FPA, SSA, T2wsi, ULN
23  2018 Dopamine Agonists for Pituitary Adenomas. D2R, NFPT
24  2018 Giant Prolactinoma in Men: Clinical Features and Therapeutic Outcomes. gPRLoma, non-gPRLomas, NS
25  2018 Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review. DRT, ICDs, PD
26  2018 Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. PRL
27  2018 Impulse control disorders in Parkinson's disease: Review of pathophysiology, epidemiology, clinical features, management, and future challenges. DBS, DDS, ICB, ICDs, PD
28  2018 Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. BAI, BDI, HC, ICD, MIDI-R, NFA
29  2018 Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant. AEs, SSA
30  2018 Longitudinal analysis of impulse control disorders in Parkinson disease. CI, ICDs, PD
31  2018 Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses. ---
32  2018 Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review. CSF
33  2018 MicroRNA-93 mediates cabergoline-resistance by targeting ATG7 in prolactinoma. ATG7, CAB
34  2018 Prolactinomas: how to handle prior to and during pregnancy? ---
35  2018 Real life evaluation of safinamide effectiveness in Parkinson's disease. COMT-I, H-Y, LD, LEDD, MAOB-I, PD, UDysRS, UPDRS-III
36  2018 The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study. DDS, LEDD, QSBB
37  2018 Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR. CBG, IHC, PRL
38  2017 ICD
39  2017 Best candidates for dopamine agonist withdrawal in patients with prolactinomas. MRI, PRL
40  2017 Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment. CAB, PRL
41  2017 Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis. MAOI, NMA, PD, SNRI, SSRI, SUCRA, TCA
42  2017 Fertility, pregnancy, and prolactinoma: A survey of pituitary surgeons' view and review of the literature. ---
43  2017 MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. ---
44  2017 Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal. PRL
45  2017 Significance of surgical management for cystic prolactinoma. ---
46  2017 Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly. PEG, SSA
47  2017 Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review. TMZ
48  2017 Wearing off: A complex phenomenon often poorly recognized in Parkinson's disease. A study with the WOQ-19 questionnaire. HY, MAOI, PD, UPDRS
49  2017 [Efficacy of Topical Agents for Symptomatic Treatment of Rotigotine Patch-Induced Skin Disorders]. ---
50  2016 A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. ICDs, PD, PPX, ROP, RTG
51  2016 A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline. IQR
52  2016 A novel surgical approach for the management of giant invasive prolactinoma compressing the brainstem. ---
53  2016 Advances in dopamine receptor agonists for the treatment of Parkinson's disease. NMS, PD
54  2016 Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. AUC, DRT, ICD, PD, ROC
55  2016 Current approach to treatments for prolactinomas. CAB, PRL
56  2016 Genetic and clinical characteristics of Japanese patients with sporadic somatotropinoma. AIP, GNAS, GPR101, SSA
57  2016 Long-term outcome of macroprolactinomas. PRL
58  2016 Molecular imaging and neural networks in impulse control disorders in Parkinson's disease. ICDs, PD
59  2016 Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson's Disease Patients: A Meta-Analysis of Randomized Controlled Trials. HF, PD, RCTs, RR
60  2016 Pasireotide for the treatment of acromegaly. SA
61  2016 Prolactinoma and pregnancy: From the wish of conception to lactation. ---
62  2016 Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist. LD
63  2016 Serum vaspin and adiponectin levels in patients with prolactinoma. ---
64  2016 Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology. PD
65  2016 The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study. EOPD, HCs, ICBs, ICDs, QOL, QUIP
66  2016 The higher incidence of autoimmune thyroid disease in prolactinomas than in somatotrophinomas. ATD, FPA, PRL, TgAb, TPOAb
67  2016 The safety of treatments for prolactinomas. CAB, PD
68  2016 Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. NFPA, PT, RT
69  2016 Treatment Options in Intractable Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED). RLS/WED
70  2016 Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when? PRL
71  2016 [Continued Use of Rotigotine Transdermal Patches for Parkinson Disease]. ---
72  2015 A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. DAWS, PD
73  2015 Association of time-to-levodopa with initial Parkinsonian medication: a retrospective cohort study. CI, HR, MAO-B, PD
74  2015 Characteristics of dynamic magnetic resonance image enhancement in prolactinomas resistant to dopamine agonist therapy. dMRI, PPS
75  2015 Combination of Exercise Training and Dopamine Agonists in Patients with RLS on Dialysis: A Randomized, Double-Blind Placebo-Controlled Study. RLS
76  2015 Current indications for the surgical treatment of prolactinomas. ---
77  2015 Current therapies and mortality in acromegaly. SRA
78  2015 Gamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. GKRS
79  2015 Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. PRL
80  2015 Management of macroprolactinomas. CSF, PRL
81  2015 Managing Prolactinomas during Pregnancy. ---
82  2015 Parkinson's disease severity and use of dopaminergic medications. GST, LD, PD
83  2015 Piribedil and pathological gambling in six parkinsonian patients. ICD, PD, PG
84  2015 Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease. DRFD, LD, PD
85  2015 Serum Ferritin Levels in Parkinson's Disease Patients with and without Restless Legs Syndrome. PD, PD-nonRLS
86  2015 Treatment of prolactinomas in low-income countries. PRL
87  2015 Treatment outcome results from the Bulgarian Acromegaly Database: adjuvant dopamine agonist therapy is efficient in less than one fifth of non-irradiated patients. GHRA, SSA
88  2014 Behavioral and neurophysiological effects of transdermal rotigotine in atypical parkinsonism. AEs, APS, CBS, MSA, MSA-C, MSA-P, PSP, RBD, RTG
89  2014 Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene? MRI
90  2014 Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine. D2S
91  2014 Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions. DDT, GNG, PD
92  2014 Dopaminergic agonists in Parkinson's disease. PD, UPDRS
93  2014 Extensive experience in the management of macroprolactinomas. ---
94  2014 Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review. GD, PD, PG
95  2014 Initial medication in patients of newly diagnosed Parkinson's disease in Taiwan. LD, PD
96  2014 Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth? PRL
97  2014 Maladaptive reward-learning and impulse control disorders in patients with Parkinson's disease: a clinical overview and pathophysiology update. ICD, PD
98  2014 Newer dopaminergic agents cause minimal endocrine effects in idiopathic Parkinson's disease. IPD
99  2014 Pooled analysis of phase III with entacapone in Parkinson's disease. PD
100  2014 Pramipexole extended-release: a review of its use in patients with Parkinson's disease. ER, IR, PD